The International Genomics of Alzheimer’s Project (IGAP) is releasing the summary results data from the Alzheimer’s disease GWAS of Kunkle et al. , Nat Genet, 2019 analysis in order to enable other researchers to examine particular variants or loci for their evidence of association.

There are two datasets are provided. The first one corresponds to the meta-analysis results obtained in stage 1 including genotyped and imputed data (11,480,632 variants, phase 1 integrated release 3, March 2012) of 21,982 Alzheimer’s disease cases and 41,944 cognitively normal controls. The second one corresponds to the meta-analysis results of the 11,632 variants that were genotyped on the I-select chip and tested for association in an independent set of 8,362 Alzheimer’s disease cases and 10,483 controls with the combined stage1/stage2 P-values. 11,540 of the I-select chip variants were available for meta-analysis with the stage 1 dataset. The Stage 3A (n = 11,666) and Stage 3B (n = 30,511) (for variants in regions not well captured on the I-select chip) results are available in the manuscript. The final sample was 35,274 clinical and autopsy-documented Alzheimer’s disease cases and 59,163 controls.
Although the individual datasets examined excluded any SNPs with call rates <95%, IGAP meta-analysis only analyzed SNPs either genotyped or successfully imputed in at least 30% of the AD cases and 30 %of the control samples across all datasets.